Zentalis Pharmaceuticals Llc Stock Analysis

Zentalis Stock Analysis Notes

About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.7. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zentalis Pharmaceuticals recorded a loss per share of 2.61. The entity had not issued any dividends in recent years. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people. For more information please call Kimberly MD at 212 433 3791 or visit https://zentalis.com.

Zentalis Pharmaceuticals Investment Alerts

Zentalis Pharmaceuticals Upcoming and Recent Events

Zentalis Largest EPS Surprises

View All Earnings Estimates

Zentalis Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Zentalis Stock Institutional Investors

Note, although Zentalis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Zentalis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 258.69 M.

Zentalis Profitablity

Management Efficiency

Zentalis Pharmaceuticals has return on total asset (ROA) of (0.2524) % which means that it has lost $0.2524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4289) %, meaning that it created substantial loss on money invested by shareholders. Zentalis Pharmaceuticals' management efficiency ratios could be used to measure how well Zentalis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.56. The value of Return On Capital Employed is expected to slide to -0.54. At this time, Zentalis Pharmaceuticals' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 10 M this year, although the value of Non Current Assets Total will most likely fall to about 54.9 M.

Technical Drivers

As of the 28th of November, Zentalis Pharmaceuticals maintains the Downside Deviation of 5.44, market risk adjusted performance of 0.1657, and Mean Deviation of 4.2. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zentalis Pharmaceuticals Llc, as well as the relationship between them. Please check out Zentalis Pharmaceuticals information ratio and downside variance to decide if Zentalis Pharmaceuticals is priced fairly, providing market reflects its latest price of 3.63 per share. Given that Zentalis Pharmaceuticals Llc has jensen alpha of 0.1087, we strongly advise you to confirm Zentalis Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.

Zentalis Pharmaceuticals Price Movement Analysis

Zentalis Pharmaceuticals Insider Trading Activities

Zentalis Pharmaceuticals Outstanding Bonds

Zentalis Pharmaceuticals Predictive Daily Indicators

Zentalis Pharmaceuticals Corporate Filings

Zentalis Pharmaceuticals Forecast Models

Zentalis Pharmaceuticals' time-series forecasting models are one of many Zentalis Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zentalis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Zentalis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zentalis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Zentalis Pharmaceuticals. By using and applying Zentalis Stock analysis, traders can create a robust methodology for identifying Zentalis entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Zentalis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Zentalis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Zentalis Pharmaceuticals Llc stock analysis indicators help investors evaluate how Zentalis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Zentalis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Zentalis Pharmaceuticals stock analysis, traders can identify Zentalis Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.